Galenus NanoGVA best poster award goes to Silvana Geisshüsler!
Congratulations to our doctoral student Silvana! She successfully developed a model vaccine that induced T-cells response in vitro and in vivo models. Activating patient's own immune system can be exploited in therapeutic cancer vaccination and other diseases.
Silvana is working on a particulate vaccine delivery platform based on the well-established excipient cyclodextrin. She synthesized amphiphilic cyclodextrins and formed nanoparticles to deliver model antigen peptides to antigen presenting cells. In collaboration with immunologists at ETH and University Hospital Zürich, she tested the system in vitro and in vivo.
The developed model vaccine showed induction of T-cell immune responses which are needed for example in therapeutic cancer vaccination and could be promising to exploit in other T-cell activation dependent diseases.